364 related articles for article (PubMed ID: 34026622)
21. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
22. Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.
Chou WC; Hu LY; Hsiung CN; Shen CY
Carcinogenesis; 2015 Aug; 36(8):832-40. PubMed ID: 26025911
[TBL] [Abstract][Full Text] [Related]
23. Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.
Chan Wah Hak CML; Rullan A; Patin EC; Pedersen M; Melcher AA; Harrington KJ
Front Oncol; 2022; 12():971959. PubMed ID: 36106115
[TBL] [Abstract][Full Text] [Related]
24. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
25. DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Min A; Lee KH; Im SA
Adv Exp Med Biol; 2021; 1187():159-179. PubMed ID: 33983578
[TBL] [Abstract][Full Text] [Related]
26. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
27. Progress towards a clinically-successful ATR inhibitor for cancer therapy.
Barnieh FM; Loadman PM; Falconer RA
Curr Res Pharmacol Drug Discov; 2021; 2():100017. PubMed ID: 34909652
[TBL] [Abstract][Full Text] [Related]
28. The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Majd NK; Yap TA; Koul D; Balasubramaniyan V; Li X; Khan S; Gandy KS; Yung WKA; de Groot JF
Neurooncol Adv; 2021; 3(1):vdab015. PubMed ID: 33738447
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.
Clark CA; Yang ES
J Immunother Precis Oncol; 2023 Feb; 6(1):31-49. PubMed ID: 36751656
[TBL] [Abstract][Full Text] [Related]
30. PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses.
Knelson EH; Patel SA; Sands JM
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578789
[TBL] [Abstract][Full Text] [Related]
31. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
32. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
Jurkovicova D; Neophytou CM; Gašparović AČ; Gonçalves AC
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499000
[TBL] [Abstract][Full Text] [Related]
33. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
34. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
35. An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein.
Nebenzahl-Sharon K; Sharf R; Amer J; Shalata H; Khoury-Haddad H; Sohn SY; Ayoub N; Hearing P; Kleinberger T
J Virol; 2019 Oct; 93(19):. PubMed ID: 31315986
[TBL] [Abstract][Full Text] [Related]
36. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
37. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
38. Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer.
Sunkara T; Bandaru SS; Boyilla R; Kunadharaju R; Kukkadapu P; Chennamadhavuni A
Cureus; 2022 Feb; 14(2):e22575. PubMed ID: 35228986
[TBL] [Abstract][Full Text] [Related]
39. Alterations of DNA damage repair in cancer: from mechanisms to applications.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Ann Transl Med; 2020 Dec; 8(24):1685. PubMed ID: 33490197
[TBL] [Abstract][Full Text] [Related]
40. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
